• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHANG Yu,MA Shaoqing.Challenges and optimized paths of China's innovative drug review mechanism[J].Journal Of Pharmaceutical Research,2026,45(5):531-535,586[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1709times   Download 800次 QR Code for this article
Scan with your phone!
我国创新药审评机制的挑战与优化路径
张宇,马韶青
Font:Larger+|Default|Smaller-
(北京中医药大学人文学院,北京 102488)
摘要:
当前我国正处于制药大国向制药强国转型的关键时期,创新药审评机制改革成效显著,法规政策持续完善、审评标准不断细化、审评效率大幅提升,但仍面临部分法规可操作性不足、前沿领域审评标准滞后、智慧审评落地不足等挑战。本文深入剖析现实困境,从细化法规内容、完善前沿领域标准、加强队伍建设、深化大数据人工智能与审评业务融合等方面提出优化路径,以期为创新药审评机制的优化贡献部分理论参考。
关键词:  创新药  审评机制  审评标准  审评队伍  智能审评
DOI:10.13506/j.cnki.jpr.2026.05.008
基金项目:北京中医药大学2025年度基本科研业务费项目(No.2025-JYB-PY-009);北京市法学会2025年市级法学研究专项课题[No.BLS(2025)B019]
Received Date:August 02, 2025   Revision Date:September 29, 2025   Publication Date:May 29, 2026
Challenges and optimized paths of China's innovative drug review mechanism
ZHANG Yu,MA Shaoqing
(School of Humanities, Beijing University of Chinese Medicine, Beijing 102488,China)
Abstract:
Currently, China is in a critical period of transitioning from a major pharmaceutical country to a powerful pharmaceutical nation.The reform of the innovative drug evaluation mechanism has achieved remarkable results, with continuous improvement in regulations and policies, refinement of evaluation standards, and significant enhancement in evaluation efficiency. However, there are still challenges such as insufficient operability of some regulations, lagging evaluation standards in frontier fields, and inadequate implementation of intelligent evaluation. This article delves into the current predicaments and proposes optimization paths from refining regulatory content, improving standards in frontier fields, strengthening team building, and deepening the integration of big data, artificial intelligence, and evaluation business. It aims to provide some theoretical references for the optimization of the innovative drug evaluation mechanism.
Key words:  Innovative drugs  Review mechanism  Review standards  Review team  Intelligent review
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.